Analyst Josh Jennings of TD Cowen maintained a Buy rating on Humacyte, retaining the price target of $3.50.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Josh Jennings has given his Buy rating due to a combination of factors that highlight Humacyte’s promising advancements and strategic positioning in the vascular therapy market. The company’s recent performance at the VEITH symposium underscored the clinical momentum of their Symvess platform, which has shown significant potential in regenerative biology and high-acuity trauma applications.
Humacyte’s ability to present a wide array of evidence supporting Symvess as a regenerative vascular conduit across various indications was a key factor in Jennings’s positive outlook. The symposium provided a valuable opportunity for the company to engage with leaders in vascular surgery and endovascular therapy, thereby enhancing their clinical outreach and setting the stage for future trial recruitment and market adoption. These developments collectively suggest a strong growth trajectory for Humacyte, justifying the Buy rating.
In another report released on November 13, Benchmark Co. also maintained a Buy rating on the stock with a $11.00 price target.